ORKA NASDAQ
Oruka Therapeutics, Inc.
1W: +21.1%
1M: +13.8%
3M: +8.8%
YTD: +238.9%
1Y: +251.6%
3Y: +631.4%
5Y: +441.9%
$95.81
+5.48 (+6.07%)
Pre-Market: $101.66 (+5.85, +6.11%)
Weekly Expected Move ±6.7%
$69
$75
$80
$86
$91
Credit Risk of going bust: lower than 89% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$6.3B
52W Range25.23-115.52
Volume1,205,199
Avg Volume1,099,510
Beta-0.39
Dividend—
Analyst Ratings
Company Info
CEOLawrence Otto Klein
Employees68
SectorHealthcare
IndustryBiotechnology
IPO Date1997-08-08
Websiteorukatx.com
855 Oak Grove Avenue
Menlo Park, CA 94025
US
Menlo Park, CA 94025
US
203-554-7604
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest News
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results - Yahoo Finance
Oruka Therapeutics, Inc. - Common Stock (ORKA) Stock Price, News, Quote & History - FinancialContent
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study - Yahoo Finance
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Quinlan Paul T | S-Sale | 400 | $74.90 | 2026-10-20 |
| Quinlan Paul T | S-Sale | 500 | $76.12 | 2026-10-20 |
| Quinlan Paul T | S-Sale | 1,000 | $77.20 | 2026-10-20 |
| Quinlan Paul T | S-Sale | 4,100 | $78.79 | 2026-10-20 |
| Quinlan Paul T | S-Sale | 3,000 | $79.49 | 2026-10-20 |